-Polyphosphate significantly augments the plasminogen activator capacity of factor XIIa.
Introduction
The contact pathway is comprised of factor XII (FXII), prekallikrein (PK), factor XI (FXI) and a non-enzymatic cofactor, high molecular weight kininogen (HK).
Reciprocal proteolytic activation of FXII and PK to their active forms, FXIIa and kallikrein respectively, occurs via interaction with a negatively charged surface and is enhanced by Zn 2+ . [1] [2] [3] [4] [5] FXI and PK circulate in complex with HK, 6, 7 which assembles these proteases on the activating surface. FXIIa can cleave FXI stimulating the intrinsic pathway and downstream generation of thrombin, leading to its classification as a coagulation factor. However, FXIIa is reported to participate in multiple pathways including inflammation, complement and fibrinolysis. 8 The profibrinolytic effects of the contact pathway are multifaceted involving direct and indirect interactions. Kallikrein liberates the vasoactive peptide bradykinin from HK which induces a host of vascular responses, including release of tissue plasminogen activator (tPA) from endothelial cells. 9 Kallikrein also directly cleaves single-chain urokinase (scuPA) 10, 11 to active uPA. FXII shows distinct homology to tPA and uPA [12] [13] [14] and in accordance with this FXIIa exhibits plasminogen activator activity. The kinetics of the reaction are considered unfavourable 13, 15 but it is present in plasma at four orders of magnitude higher concentrations compared to tPA and uPA. 16, 17 During evolution, redundancy has developed in the fibrinolytic system, underscored by the relatively mild abnormalities associated with deficiency in tPA or uPA, while the double knockout exhibits a more acute phenotype. 18 Under certain circumstances or within specific milieus it is plausible that FXIIa contributes to plasmin generation to complement or compensate for tPA and uPA activity and may be potentially relevant in vivo. 19 Several natural surfaces facilitate FXII activation including polyphosphate (polyP), 20, 21 RNA, 22 misfolded proteins 23 and collagen. 24 PolyP is an ancient biomolecule that is ubiquitous in nature 25 it is highly anionic and consequently acts as a propitious surface for activation of the contact pathway. 20, 21 PolyP is localized in platelet dense granules 26 and is secreted upon activation 21 alongside ADP, serotonin, and metal ions, including Zn 2+ . Platelet polyP is approximately 60-100 mers 21 which is significantly shorter than the long-chain polymers (1000-2000 mers) in bacteria. 27 Polymer length is crucial to polyP's biological activity with shorter chains showing reduced capacity to activate the contact pathway. 28 PolyP also interacts with fibrin(ogen) and accumulates in clots altering their structural properties and susceptibility to tPA-mediated fibrinolysis. 29, 30 The half-life of polyP in plasma is relatively short (1.5-2 h) 20 but could be preserved within the microenvironment of the thrombus.
The plasminogen activator function of FXIIa is augmented by artificial surfaces and Zn 2+ . 31 Here, for the first time, we show that a natural surface, polyP, amplifies the plasminogen activator function of FXIIa. Indeed polyP, of approximate chain length of that found in platelets, binds both FXII(a) and plasminogen, indicative of a template mechanism of activation. Importantly, we also demonstrate that plateletassociated fibrin acts as a reservoir for FXII(a), plasminogen and platelet-released polyP.
Methods

Collection of blood and preparation of plasma & platelets
For platelet experiments, peripheral blood was collected into acid citrate dextrose (ACD) solution A vacuettes (Greiner Bio-one LTD); the first 3 ml was discarded.
Platelets were washed and counted as described. 32 Pooled normal plasma (PNP) that is essentially free of platelets was prepared from whole blood of 20 normal donors collected into 3.2% trisodium citrate. 33 
PolyP preparation
PolyP was extracted from platelets as described. 28 Experiments were performed with platelet-derived polyP, synthetic polyP65 (Sigma-Aldrich) or polyP70 (a kind gift from BK Giulini, GmbH). Similar results were obtained with both synthetic preparations and for simplicity are described as polyP70 throughout and the concentration quoted as phosphate monomer (monomer formula, NaPO3).
Clot lysis
Plasminogen-depleted fibrinogen (3.8 µM), Glu-or Lys-plasminogen (0.24 µM) and αFXIIa (200 nM) were added ± polyP70 (70 µM) in 10 mM Tris-HCl [pH 7.4], 140 mM NaCl and 0.01% Tween 20 to 96-well plates (Greiner). Clotting was initiated with 0.25 U/ml human thrombin and 10 mM CaCl2. In an analogous set of experiments 200 nM FXII was pre-incubated with polyP70 (140 µM) at ambient temperature for 30 min.
In some cases tPA (1 pM) was also included. Some experiments incorporated the inhibitors PAI-1 (0.1-1 nM), PAI-2 (0.1-1 nM), C1 inhibitor (125-500 nM) or histidinerich glycoprotein (HRG; 0.25-1 µM). PolyP70 was replaced by HeLa RNA (10 µg/ml) or equine type 1 (Horm) collagen (5 µg/ml) in some assays. Absorbance at 405 nm was recorded every minute using a BioTek PowerWave plate reader and BioTek Gen5 software.
Plasminogen activation assay
Plasminogen activation was analysed as described 30 with the following modifications.
αFXIIa (200 nM), Glu-or Lys-plasminogen (0-400 nM) and S2251 (0.5 mM) were added to microtiter plates in 10 mM Tris-HCl [pH 7.4], 140 mM NaCl and 0.01% Tween 20 ± polyP70 (0-70 µM). Alternatively, 200 nM FXII was added ± polyP70 (140 µM). Plasmin activity was detected by measuring the absorbance at 405 nm every 1 min. In a parallel set of assays the following inhibitors; PAI-1 (0.1-1 nM), PAI-2 (0.1-1 nM), C1 inhibitor (125-500 nM) and HRG (0.25-1 µM) were incorporated. In some experiments soluble fibrin (3.8 µM), prepared as described 34 was coated onto plates overnight at 4°C before performing activity assays. In some cases RNA (10 µg/ml) or collagen (5 µg/ml) were included in place of polyP70.
FXIIa activity assay
FXIIa activity was analysed as described, 35 briefly αFXIIa (50 nM) and S2302 (0.25 mM) ± polyP70 (70 µM) were added to microtiter plates and absorbance read at 405 nm for 4 h, with addition of 5 μl (5 mM) S2302, or 5 μl (50 nM) protein at the 2 h midpoint.
Gels and binding assays
In autodegradation experiments, αFXIIa (50 nM) was incubated ± polyP70 (1 µM) for up to 360 min before resolving on 4-12 % Bis-Tris gels (NuPAGE, Life Technologies) under non-reducing conditions and protein stained using InstantBlue ™ .
PolyP70 was bound to Sepabeads as described 36 and incubated with 5 µg of FXII, αFXIIa, βFXIIa or plasminogen. Flow through material and subsequent low salt (50 mM NaCl) and high salt (1 M NaCl) washes were collected and fractions analysed by Western blotting as described 37 using HRP-conjugated goat anti-human FXII (ERL) or HRP-conjugated goat anti-human plasminogen (ERL).
Visualization of FXII and polyP on single platelets
Slides were coated with collagen (20 µg/ml) and thrombin (100 nM) and subsequently blocked with 5% bovine serum albumin. Platelets (5 x 10 7 /ml) were added to coated slides for 45 Ex. 562, Em. 576). Thrombin (24 nM) and CaCl2 (10 mM) were added and clots were allowed to form in Ibidi µ-slide VI 0.4 ibiTreat chambers for 2 h. Images were recorded as detailed above for single platelets.
FXII and platelet polyP distribution in plasma clots
Flow Cytometry
DL488-FXII (365 nM), and DAPI (10 µg/ml) were added to washed platelets (2 x 
Data analysis
Data analysis was performed in GraphPad Prism ® 5.04. Clot lysis results are expressed as time to 50% lysis (CLT), derived from the time taken from the maximal amplitude of the clot to reach the midpoint to baseline. Alternatively, graphs were normalised and data plotted as % turbidity. Plasmin generation was calculated as described 38 , briefly, absorbance at 405 nm was plotted against time-squared and the slope from the initial linear portion estimated. These values were used to calculate plasminogen activation rates using the specific activity of plasmin against S2251 that was experimentally determined to be 1.055 A405/min/µM (not shown). Fold-changes in lysis were calculated from mean CLT data. Statistical analysis was performed on CLT, plasmin activity assays and flow cytometry data using student's t-test or when multiple parameters were tested one-way analysis of variance with Dunnett's Multiple comparison post-hoc test. P values of < 0.05 were considered significant.
Results
αFXIIa plasminogen activator activity is enhanced by polyP70
Artificial surfaces can enhance the plasminogen activator capacity of αFXIIa. 31 This prompted us to examine the effect of the 'natural' activator polyP, of approximate size (60-100-mers) of that found in platelets, in αFXIIa-mediated plasminogen activation. In line with previous observations we show that αFXIIa is a relatively weak plasminogen activator. 13, 15 However, inclusion of polyP70 significantly augments the ability of αFXIIa to drive fibrinolysis, decreasing the CLT by 2.3-fold (105 ± 6 min vs. 238 ± 14 min; P<0.0001; Figure 1A ). Similarly, polyP70 accelerated αFXIIa-mediated plasmin generation ( Figure 1B ; P<0.0001) in a dose-dependent manner, with concentrations as low as 4.4 µM demonstrating a significant enhancement over αFXIIa alone ( Figure 1C ; P<0.0001). PolyP had no direct effect on the activity of preformed plasmin ( Figure 1D ; P=0.93). This indicates that polyP70 accelerates αFXIIa-mediated conversion of plasminogen to plasmin. The derivative, βFXIIa, lacks the surface binding domain and is less efficient at stimulating plasminogen activation. 16 The low level of plasmin generation observed with βFXIIa was not augmented by polyP70, reflecting the requirement of the anion binding domain of αFXIIa for interaction with polyP70 ( Figure 1E ; P=0.71). Inclusion of Zn 2+ in the reaction buffer did not further enhance the cofactor function of polyP70 in this reaction (not shown). We found that platelet-derived polyP extracted from human platelets similarly enhanced the plasminogen activator capacity of αFXIIa ( Figure 1 F).
As polyP is a known activator of FXII 20, 21, 35 we examined its capacity to both stimulate FXII activation and subsequently stimulate its plasminogen activator function. CLT were significantly longer with FXII (>300 min) compared to αFXIIa (238 ± 58 min) and similarly, rates of plasmin generation were significantly lower with FXII compared to αFXIIa, presumably reflecting the time for transition of zymogen to protease. Nevertheless, polyP70 exhibits significant cofactor activity in clot lysis and activity assays when initiated with FXII-polyP rather than FXII alone ( Figure 2A ).
We next investigated binding of polyP70 to FXII derivatives and found it complexed with FXII and αFXIIa, but not βFXIIa; confirming the critical role of the anion binding site for this interaction ( Figure 2B ). When in complex with polyP70 autodegradation of αFXIIa was delayed ( Figure 2C ). The protective effect of polyP70 on αFXIIa was analysed using S2302 substrate ( Figure 2D ). Addition of excess substrate to the αFXIIa reaction at 2 h generated a further increase in absorbance in the presence of polyP70 while no change was observed with αFXIIa alone. No further increase in activity was observed when additional αFXIIa was added to reactions with polyP70 at 2 h, confirming that protein is not limiting (not shown). We further analysed changes in αFXIIa activity in terms of cleavage of FXI, but were unable to detect any changes in FXI activation after 360 min incubation in the absence or presence of polyP70 (not shown). These data indicate that while polyP70 confers protection against autodegradation the differences may be too minor to alter functional activity toward physiological targets.
αFXIIa enhances activation of Glu-and Lys-forms of plasminogen
We found that plasminogen bound immobilized polyP70, and could be released by washing with high salt buffer ( Figure 3A ). This is indicative of an electrostatic interaction with the polymer, as previously shown for other proteins. 30, 34, 36 Plasminogen circulates in two forms; the predominant Glu-plasminogen is described as the 'closed' conformation, while the truncated Lys-plasminogen, cleaved at the Cterminus by plasmin, is in an 'open' conformation and exhibits a shorter half-life.
Enhanced binding of Lys-plasminogen to fibrin 39 and activators tPA and uPA results in more rapid plasmin generation 40, 41 . We observed faster plasmin generation and clot lysis with Lys-plasminogen (catalytic efficiency (CE) = 257.5 ± 21.0 M -1 s -1 ) than Glu-plasminogen (CE = 18.5 ± 4.2 M -1 s -1 ) when activated with αFXIIa (note the different scales in Figure 3B -C). PolyP70 significantly augmented αFXIIa-mediated activation of Glu-plasminogen (CE = 41.1 ± 6.0 M -1 s -1 ) and Lys-plasminogen (CE = 629.5 ± 75.6 M -1 s -1 ) ( Figure 3B ) and accelerated clot lysis with both forms by ~2.6fold ( Figure 3C ). These data suggest that polyP does not impact on the transition of the closed (Glu) to open (Lys) conformation of plasminogen, but directly facilitates cleavage to plasmin.
PolyP70 and fibrin augment αFXIIa-mediated plasminogen activation
We have previously shown that polyP binds to fibrin(ogen) and alters the structure of the fibrin network 34 and therefore assessed the impact on αFXIIa-mediatedplasminogen activation. Fibrin significantly enhanced the plasminogen activator function of αFXIIa ( Figure 4A ) and when combined, fibrin and polyP70 acted in concert to further amplify αFXIIa-mediated plasminogen activation ( Figure 4A ;
We analysed whether other natural surfaces that stimulate FXII activation, such as RNA 22 , and collagen 24 modulated the plasminogen activator function of αFXIIa. RNA slightly enhanced plasmin generation by αFXIIa ( Figure 4B ; P<0.001), but not to the same magnitude as polyP70, while collagen was unable to stimulate activation.
However, neither collagen nor RNA was effective in shortening the CLT like polyP70 ( Figure 4C ; P<0.001).
We next addressed whether αFXIIa acted in concert with tPA to mediate fibrinolysis.
Inclusion of αFXIIa with a concentration of tPA (15 pM) sufficient to induce clot lysis further shortened the CLT from 69 ± 8.6 min to 47 ± 2.7 min (P<0.01; CLT of αFXIIa alone >300 min). We then performed assays at a suboptimal dose of tPA (1 pM) which alone were not sufficient to induce lysis (CLT>300 min). Addition of αFXIIa to clots containing 1 pM tPA significantly shortened the CLT (180 ± 9.4 min), but not to the extent of polyP70 (106 ± 6.5 min P<0.0001; Figure 4D ). A marginal decrease in CLT was observed with both αFXIIa and t-PA in the presence of polyP70 (97 ± 1.4 min; P<0.01). Similarly, visualisation of lysis in real-time (Video 1) demonstrated significantly faster lysis in the presence of both αFXIIa and tPA compared to tPA alone. Interestingly, the pattern of lysis in the presence of αFXIIa was different, with clots lysing from the edge inwards, rather than proceeding with a defined lysis front as observed with tPA alone. These data illustrate that fibrin degradation is enhanced in the presence of both tPA and αFXIIa, compared to either activator alone.
C1 inhibitor and HRG regulate the plasminogen activator activity of αFXIIa
Inclusion of the plasminogen activator inhibitors, PAI-1 and PAI-2, at plasma concentrations did not impact αFXIIa-mediated lysis ( Figure 5A ) or plasmin generation ( Figure 5B ) in the absence (not shown) or presence of polyP70 ( Figure   5A ). In contrast, C1 inhibitor significantly attenuated αFXIIa-mediated clot lysis ( Figure 5A ; P<0.0001) and plasmin generation ( Figure 5B ; P<0.001) ± polyP70. HRG was also effective in down-regulating CLT ( Figure 5A ; P<0.0001) and plasminogen activation ( Figure 5B ; P<0.001) by αFXIIa ± polyP70. The inhibition of αFXIIamediated plasminogen activation by α2AP could not be examined due to its dominant inhibition of plasmin, but we found no discernible effects on direct inhibition of αFXIIa ± polyP70 using S2302 (not shown).
FXII and polyP bind to the surface of stimulated platelets
We examined the interaction of DL488-FXII with platelets by flow cytometry and found that binding to CVX/thrombin stimulated platelets was significantly augmented compared to unstimulated (62.6 ± 6.9% versus 22.4 ± 13.5%; P<0.0001; Figure 6A ).
Platelets stimulated with CVX/TRAP-6 displayed a reduced capacity to bind DL488-FXII (44.7 ± 8.9%; P<0.01). Inclusion of GPRP, to impede fibrin polymerisation, markedly decreased the percentage of CVX/thrombin stimulated platelets that bound DL488-FXII (33.4 ± 6.9%; P<0.0001). Together these data suggest platelet-bound fibrin plays a crucial role in the association of FXII with the activated platelet surface.
We found a significantly higher degree of positivity for platelet-derived polyP on the surface of CVX/thrombin compared to unstimulated (52 ± 2% versus 8.1 ± 4.0%;
P<0.0001). Surface-bound polyP was slightly decreased when platelets were stimulated with CVX/TRAP-6 (37.1 ± 7.2%; P<0.01) and upon inclusion of GPRP (31.5 ± 12.1%; P<0.01) suggesting a role for platelet-bound fibrin in its retention on the activated platelet membrane ( Figure 6B ).
Using fluorescence confocal microscopy we examined the localization of FXII on the activated platelet surface stimulated with CVX/thrombin. Phosphatidylserine (PS)positive platelets bound DL488-FXII in a single protruding 'cap' on the platelet surface that is also rich in PS ( Figure 6C and Video 2). DL488-FXII also bound to PS-negative, spread platelets in a central diffuse pattern over the area of the granulomere ( Figure 6D ). Staining for platelet-derived polyP was dispersed over the activated membrane of PS-positive platelets ( Figure 6E) . Control experiments performed with nuclease, to degrade contaminating DNA and RNA, did not alter DAPI staining on activated platelets (Supplemental Figure S1 ).
Platelet-derived polyP associates with the platelet surface in clots and co-localises with FXII on adjacent fibrin fibres
The location of platelet-derived polyP and FXII was studied in plasma clots formed in the presence of activated platelets. Platelet-derived polyP associates with the surface of activated platelets, particularly procoagulant PS-positive platelets and on platelet-bound fibrin ( Figure 6F .) No DAPI staining was observed in clots formed in the absence of platelets (data not shown). DL488-FXII also decorated fibrin fibres extending from platelet aggregates in clear co-localization with platelet-derived polyP.
Discussion
In the present study we reveal a cofactor function for platelet-derived polyP in modulating the plasminogen activator activity of αFXIIa. Platelet-derived polyP colocalised with αFXIIa on the fibrin matrix extending from platelet aggregates.
Blocking fibrin polymerisation with GPRP reduced binding of FXII, highlighting its importance in accrual of FXII in platelet-rich areas. Our findings demonstrate that in the presence of platelet polyP, αFXIIa is an efficient plasminogen activator. In addition we show that fibrin augments the plasminogen activator capacity of αFXIIa in a synergistic manner to polyP. There have been several reports on modulation of fibrinolysis by polyP 20, 29, 30 but to our knowledge this is the first study to document a profibrinolytic function of platelet-derived polyP.
The plasminogen activator function of αFXIIa has been described previously 15, 16, 31 , but has been largely ignored due to unfavourable kinetics. Despite displaying a 20fold lower catalytic efficacy for plasminogen than uPA the relative abundance of FXII (375 nM) in plasma implies it may be relevant as a plasminogen activator. 17 Nevertheless, studies on the role of αFXIIa as a direct plasminogen activator are limited. 19, 42, 43 Here we demonstrate that polyP, of approximately the size found in platelets, and platelet-derived polyP, significantly augment αFXIIa-mediated plasmin generation. PolyP accelerates αFXIIa-mediated activation of Glu-and Lysplasminogen to a similar degree indicating that it does not facilitate transition of the closed to open conformation and nor does it directly impact on plasmin activity. We observed binding of polyP to FXII(a) and plasminogen indicating that the cofactor function of this polymer is potentially mediated via a template mechanism on direct conversion of plasminogen to plasmin (Figure 7) . PolyP also stimulates autoactivation of FXII to αFXIIa 35 and indeed affords some protection against autodegradation. This could be relevant in terms of time frame, as FXII may become activated during clot formation, however by interacting with platelet-derived polyP its activity may be protected allowing it to subsequently participate in clot degradation.
Indeed a recent publication highlighted the dual role of FXII in supporting fibrin
formation and degradation of the clot. 44 It is interesting to speculate on the complex role of this enzyme in modulating both fibrin formation, via generation of thrombin, and fibrin degradation via plasmin. Further work is necessary to define the procoagulant and profibrinolytic properties of αFXIIa and the role of effector molecules, such as polyP, in these processes. Indeed opposing functions of a haemostatic enzyme is not an uncommon phenomenon. The central enzyme thrombin is a prime example as its activity can be directed from procoagulant to anticoagulant processes depending on the effector molecule bound to exosite I or exosite II of the protease. 45 Fibrin also amplifies αFXIIa-mediated plasminogen activation, with maximal stimulation observed when both fibrin and polyP are present; suggesting that these molecules act synergistically to drive this process. PolyP has the capacity to bind to fibrin 29, 30 and FXII(a) but these observations indicate that their respective binding sites on FXII(a) must be distinct. Fibrin is a well-established cofactor for tPAmediated plasminogen activation. αFXIIa was able to act in conjunction with tPA to significantly accelerate fibrinolysis, suggesting that incorporation of these activators into the forming fibrin network may facilitate clot degradation, as depicted in the model shown in Figure 7 . Interestingly, other surfaces that promote FXII activation and procoagulant function, specifically collagen 24 and RNA 22 , were not effective in promoting αFXIIa-mediated fibrinolysis. This suggests that cofactors molecules may drive αFXIIa activity toward distinct downstream target substrates.
Antifibrinolytic functions of polyP have been described in the past. 20, 29, 30 The first of these relates to enhanced activation of thrombin activatable fibrinolysis inhibitor (TAFI), due to acceleration of thrombin generation in the presence of polyP. 20 Activated TAFI down-regulates fibrinolysis by removing C-terminal lysine residues on fibrin that are important for binding plasminogen and tPA. 46 PolyP also exerts antifibrinolytic function by altering the structure of the forming fibrin network. 29, 30 Our recent work has shown that this arises from impaired fibrin polymerisation. 47 The modifications to the fibrin architecture by polyP alter its capacity to bind tPA and plasminogen, particularly that of partially degraded fibrin, thereby reducing tPA mediated plasmin generation. 30 The profibrinolytic capacity of polyP described here, in terms of augmenting αFXIIa-mediated plasminogen activation, is intriguing particularly in light of the fact that fibrin also plays a role in this process. It seems that the functions of polyP are more diverse than first thought and that this polymer may exert different levels of control over the haemostatic system depending on timing and perhaps local concentrations of available reactants.
Interestingly, the plasminogen activator inhibitors, PAI-1 and PAI-2 were ineffective in modulating polyP-αFXIIa-mediated plasminogen activation and fibrinolysis while C1-inhibitor and HRG both effectively neutralised activity. C1-inhibitor is the predominant inhibitor of the contact pathway and regulates tPA-mediated plasminogen activation in situations when tPA is in excess over PAI-1. [48] [49] [50] Interestingly C1-inhibitor has also been shown to bind to polyP. 51 Recent data highlighted the important role of HRG in modulating FXIIa activity and function. [52] [53] [54] HRG binds to FXIIa with incredibly high affinity in the presence of Zn 2+ ions 52 and both are released from platelet α-granules upon activation. 55, 56 HRG also associates with DNA and RNA and attenuates nucleic acid-driven activation of FXII. 53 Here we show for the first time that HRG dampens αFXIIa activity directed toward the fibrinolytic pathway, adding to the complexity of this unusual adapter protein in regulation of haemostatic pathways.
To date the binding sites for αFXIIa on platelets have not been elucidated but unlike other coagulation factors it does not bind directly to PS-positive platelets via Gla domains. 57 We have previously shown that FXII(a) binds to fibrin and is actively incorporated into clots 58 , and elegant flow studies confirmed that FXII(a) interacts with platelet-associated fibrin. 57 We observed significantly more FXII on the surface of platelets activated with thrombin/CVX than TRAP-6/CVX. Blocking fibrin polymerisation with GPRP during thrombin/CVX stimulation, but not TRAP-6/CVX stimulation, significantly reduced the amount of FXII associated with platelets.
Together these data indicate that fibrin anchors FXII to the activated platelet membrane. PS-positive platelets display a cap of FXII on the activated surface that we have recently shown to be rich in fibrin(ogen) and plasminogen. 59 We also show that platelet-derived polyP is retained on the membrane of PS-positive platelets, but unlike FXII, fibrinogen and plasminogen, it is homogenously distributed. Inhibition of fibrin polymerisation attenuates association of polyP with the platelet surface, consistent with its known affinity for fibrin 30 but does not completely abrogate binding. This suggests the presence of a second, as yet unidentified mechanism, that mediates retention of polyP on activated platelets. Nevertheless, we also show that polyP can translocate from the 'hot-spots' of PS-positive platelets into the surrounding fibrin network. FXII also decorates fibrin strands accentuating the importance of platelet-bound fibrin in localising FXII and plasminogen 59 in the vicinity of activated platelets. Release of polyP from stimulated platelets could stimulate activation of FXII on fibrin and enhance the plasminogen activator capacity of αFXIIa; in this sense fibrin will be acting as a surface for its own destruction, as it does in t-PA mediated plasminogen activation.
Thrombi are composed of different regions, the inner 'core' and the outer 'shell' which differ in their levels of platelet activation, aggregation and packing. 60 The 'core' is comprised of tightly packed, degranulated platelets encased in fibrin. 60 ADP released from dense granules regulates α-granule secretion [61] [62] [63] forming dense regions that stabilise the platelet aggregate. 64 Concomitant release of polyP with ADP from dense granules suggests it may be retained in these low solute transport areas. α-granule release occurs at lower agonist concentrations than dense granule release 65, 66 suggesting platelets in the outer core and shell may release fibrinogen and bind fibrin prior to polyP secretion thereby providing an anchor to retain polyP in the locale of the activated platelet aggregates. This cartoon depicts the potential template interactions between αFXII(a), plasminogen and polyP on polymerized fibrin. Fibrin forms the initial network and acts as a template for both tPA and FXIIa-mediated fibrinolysis due to its capacity to bind FXII(a), polyP, plasminogen and tPA. PolyP binds to fibrin, αFXII(a) and plasminogen and potentially acts as an anchor to reinforce the association between these proteins. When αFXII(a) is bound to fibrin and polyP its activation and plasminogen-activator activity is enhanced, facilitating plasmin generation on fibrin and subsequent degradation of the network. The cofactor capacity of fibrin in the stimulation of tPA-mediated plasminogen activation is well documented. Binding of the polyP-FXII(a) complex may to further facilitate plasminogen activation on the fibrin surface to accelerate fibrinolysis.
